Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
European Society of Gynaecological Oncology (ESGO)
European Society of Gynaecological Oncology (ESGO)
The
European Society of Gynaecological Oncology
(
ESGO
) is a Europe-wide society of health care professionals and researchers specializing in the study, prevention, treatment and care of gynaecological cancers. The society, which has more than 1,000 members from over 30 European countries, was founded in Venice, Italy, in 1983.
Survival Outcomes from Delayed Cytoreduction Surgery Following Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer
ESGO 2020
Survival outcomes are not worse for patients with endothelial ovarian cancer treated with neoadjuvant chemotherapy if cytoreduction surgery is delayed beyond 3 cycles of treatment.
Read More ›
Efficacy of Niraparib Therapy in Patients with Newly Diagnosed Advanced Ovarian Cancer Based on BRCA Wild-Type Status
ESGO 2020
Niraparib improved progression-free survival when used as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer with BRCA wild-type tumors, regardless of homologous recombination status.
Read More ›
Prognostic Value of PET-CT on Survival Outcomes in Patients with Advanced Ovarian Cancer
ESGO 2020
Early preoperative PET-CT examination in patients with advanced-stage ovarian cancer treated with neoadjuvant chemotherapy may be a useful prognostic tool.
Read More ›
Targeting AKT and DNA-PK in Platinum-Resistant High-Grade Serous Ovarian Cancer
ESGO 2020
Inhibition of AKT or DNA-PK in combination with cisplatin results in reduced cell growth and proliferation. The use of AKT and DNA-PK inhibitors may improve overall survival for patients with platinum-resistant high-grade serous ovarian cancer.
Read More ›
Identifying Mechanisms Responsible for PARP Inhibitor Resistance in Ovarian Cancer
ESGO 2020
Pathways were identified that are crucial in the mechanism of PARP inhibitor resistance in patients with ovarian cancer. Key signaling kinases were identified as therapeutic targets and folate receptor 1 was identified as a potential biomarker for treatment response.
Read More ›
Diagnostic Accuracy of Serum Insulin-Like Growth Factor Binding Protein-2 for Ovarian Cancer
ESGO 2020
Insulin-like growth factor binding protein-2 (IGFBP2) was demonstrated to be a potential biomarker for the diagnosis of ovarian cancer. The assessment of preoperative serum IGFBP2 levels in patients with adnexal mass may have the potential to differentiate between malignant and benign ovarian tumors.
Read More ›
Prognostic Value of Tumor-Infiltrating Lymphocytes and Neutrophil-to-Lymphocyte Ratio in Patients with Advanced Ovarian Cancer
ESGO 2020
The combined assessment of tumor-infiltrating lymphocytes and neutrophil-to-lymphocyte ratio increases their prognostic value in patients with advanced-stage ovarian cancer. This combined prognostic factor may be useful in improving immunotherapy strategies in patients with advanced ovarian cancer.
Read More ›
Complete Surgical Cytoreduction Is Vital in Achieving Better Survival Outcomes in Women with Advanced Ovarian Cancer
ESGO 2020
This study could not confirm a favorable response to neoadjuvant chemotherapy or less extensive surgery in patients with a
BRCA
mutation. However, the data demonstrate that complete surgical cytoreduction is vital in achieving better survival outcomes in women with advanced ovarian cancer, irrespective of
BRCA
status.
Read More ›
Hematologic Adverse Events Observed with Niraparib in Advanced Ovarian Cancer
ESGO 2020
The incidence of hematologic adverse events observed in patients with advanced ovarian cancer treated with niraparib at an individualized starting dose of 200 mg once daily was lower than that reported with a dose of 300 mg once daily.
Read More ›
Real-World Data on Platinum Outcomes After PARP Inhibitor Progression in High-Grade Serous Ovarian Cancer
ESGO 2020
An analysis of real-world data suggests that patients with a platinum-free interval of ≥12 months experienced a trend toward a greater benefit from subsequent platinum-based chemotherapy after PARP inhibition. For patients with a platinum-free interval of 6 to 12 months, the benefit was similar to that seen in patients receiving nonplatinum chemotherapy.
Read More ›
Page 1 of 2
1
2
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us